Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)
CNY 12.14
(2.53%)
CNY 12.14
(2.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.28 Billion CNY | -0.34% |
| 2022 | 2.29 Billion CNY | -29.54% |
| 2021 | 3.25 Billion CNY | -3.13% |
| 2020 | 3.35 Billion CNY | 53.53% |
| 2019 | 2.18 Billion CNY | -26.48% |
| 2018 | 2.97 Billion CNY | 44.57% |
| 2017 | 2.05 Billion CNY | 35.95% |
| 2016 | 1.51 Billion CNY | 1400.53% |
| 2015 | -116.35 Million CNY | -113.89% |
| 2014 | 837.48 Million CNY | 127.2% |
| 2013 | 368.6 Million CNY | 466.07% |
| 2012 | -100.69 Million CNY | 77.8% |
| 2011 | -453.48 Million CNY | 46.63% |
| 2010 | -849.75 Million CNY | -1004.79% |
| 2009 | 93.91 Million CNY | -19.33% |
| 2008 | 116.42 Million CNY | 23.96% |
| 2007 | 93.92 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.94 Billion CNY | -11.67% |
| 2024 Q1 | 2.29 Billion CNY | 0.69% |
| 2024 Q2 | 2.24 Billion CNY | -2.51% |
| 2023 Q4 | 2.28 Billion CNY | -1.82% |
| 2023 FY | 2.28 Billion CNY | -0.34% |
| 2023 Q1 | 2.36 Billion CNY | 3.13% |
| 2023 Q2 | 2.33 Billion CNY | -1.04% |
| 2023 Q3 | 2.32 Billion CNY | -0.54% |
| 2022 Q4 | 2.29 Billion CNY | -5.61% |
| 2022 FY | 2.29 Billion CNY | -29.54% |
| 2022 Q2 | 3.1 Billion CNY | -0.58% |
| 2022 Q3 | 2.42 Billion CNY | -21.85% |
| 2022 Q1 | 3.12 Billion CNY | -3.92% |
| 2021 Q3 | 2.98 Billion CNY | -8.21% |
| 2021 FY | 3.25 Billion CNY | -3.13% |
| 2021 Q4 | 3.25 Billion CNY | 8.88% |
| 2021 Q1 | 3.08 Billion CNY | -8.12% |
| 2021 Q2 | 3.25 Billion CNY | 5.49% |
| 2020 Q1 | 2.76 Billion CNY | 26.64% |
| 2020 Q4 | 3.35 Billion CNY | 6.57% |
| 2020 FY | 3.35 Billion CNY | 53.53% |
| 2020 Q2 | 3.04 Billion CNY | 10.07% |
| 2020 Q3 | 3.15 Billion CNY | 3.36% |
| 2019 Q3 | 2.56 Billion CNY | -0.31% |
| 2019 Q4 | 2.18 Billion CNY | -14.91% |
| 2019 Q1 | 3.2 Billion CNY | 7.76% |
| 2019 Q2 | 2.57 Billion CNY | -19.58% |
| 2019 FY | 2.18 Billion CNY | -26.48% |
| 2018 Q1 | 2.76 Billion CNY | 34.37% |
| 2018 Q3 | 2.97 Billion CNY | 39.57% |
| 2018 FY | 2.97 Billion CNY | 44.57% |
| 2018 Q4 | 2.97 Billion CNY | -0.18% |
| 2018 Q2 | 2.13 Billion CNY | -22.77% |
| 2017 Q2 | 2.04 Billion CNY | 93.94% |
| 2017 Q3 | 2.23 Billion CNY | 9.16% |
| 2017 Q4 | 2.05 Billion CNY | -7.97% |
| 2017 FY | 2.05 Billion CNY | 35.95% |
| 2017 Q1 | 1.05 Billion CNY | -30.23% |
| 2016 Q1 | -68.91 Million CNY | 40.77% |
| 2016 FY | 1.51 Billion CNY | 1400.53% |
| 2016 Q4 | 1.51 Billion CNY | -23.77% |
| 2016 Q2 | 546.54 Million CNY | 893.08% |
| 2016 Q3 | 1.98 Billion CNY | 263.22% |
| 2015 Q1 | 942.3 Million CNY | 12.52% |
| 2015 Q4 | -116.35 Million CNY | 70.29% |
| 2015 FY | -116.35 Million CNY | -113.89% |
| 2015 Q2 | -558.52 Million CNY | -159.27% |
| 2015 Q3 | -391.7 Million CNY | 29.87% |
| 2014 Q3 | 828.55 Million CNY | 53.34% |
| 2014 Q2 | 540.33 Million CNY | 27.05% |
| 2014 Q1 | 425.28 Million CNY | 15.38% |
| 2014 FY | 837.48 Million CNY | 127.2% |
| 2014 Q4 | 837.48 Million CNY | 1.08% |
| 2013 Q1 | -64.64 Million CNY | 35.8% |
| 2013 FY | 368.6 Million CNY | 466.07% |
| 2013 Q2 | -32.94 Million CNY | 49.04% |
| 2013 Q4 | 368.6 Million CNY | 40.39% |
| 2013 Q3 | 262.55 Million CNY | 897.02% |
| 2012 FY | -100.69 Million CNY | 77.8% |
| 2012 Q1 | -329.69 Million CNY | 27.3% |
| 2012 Q2 | -234.2 Million CNY | 28.96% |
| 2012 Q3 | -142.3 Million CNY | 39.24% |
| 2012 Q4 | -100.69 Million CNY | 29.24% |
| 2011 Q3 | -474.57 Million CNY | 3.23% |
| 2011 Q1 | -774.02 Million CNY | 8.91% |
| 2011 FY | -453.48 Million CNY | 46.63% |
| 2011 Q4 | -453.48 Million CNY | 4.44% |
| 2011 Q2 | -490.4 Million CNY | 36.64% |
| 2010 Q3 | 175.64 Million CNY | 1.1% |
| 2010 FY | -849.75 Million CNY | -1004.79% |
| 2010 Q2 | 173.73 Million CNY | 0.0% |
| 2010 Q4 | -849.75 Million CNY | -583.79% |
| 2009 Q4 | 93.91 Million CNY | 0.0% |
| 2009 FY | 93.91 Million CNY | -19.33% |
| 2008 FY | 116.42 Million CNY | 23.96% |
| 2007 FY | 93.92 Million CNY | 0.0% |